Jassada Buaboonnam

Dr. Jassada Buaboonnam

Assoc prof
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2019 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
JBJassada Buaboonnam
Jassada Buaboonnam
PSPariwan Sripatanatadasakul
Pariwan Sripatanatadasakul
ATAjjima Treesucon
Ajjima Treesucon
WGWaraporn Glomglao
Waraporn Glomglao
PSPreeyanun Siraprapapat
Preeyanun Siraprapapat
KSKleebsabai Sanpakit
Kleebsabai Sanpakit

1 January 2021 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSutatta Supatharawanich
Sutatta Supatharawanich
NNNattee Narkbunnam
Nattee Narkbunnam
NVNassawee Vathana
Nassawee Vathana
CTChayamon Takpradit
Chayamon Takpradit
KPKamon Phuakpet
Kamon Phuakpet
JBJassada Buaboonnam
Jassada Buaboonnam
Although the outcome of childhood leukemia and severe aplastic anemia (SAA) has improved, infectious complications are still the major concern, particularly invasive fungal infection (IFI), which is one of the most common causes of infectious related death in such patients with prolonged neutropenia. A retrospective study of IFI in pediatric patients with newly diagnosed and relapsed acute leukemia and SAA in Siriraj Hospital, Mahidol University, Thailand, was conducted. There were 241 patients (150 patients with ALL, 35 patients with AML, 31 patients with relapsed leukemia and 25 patients with SAA) with the median age of 5.4 years (rage, 0.3-16.0 years). The overall prevalence of IFI was 23.2%, and the breakdown prevalence in ALL, AML, relapsed leukemia and SAA were 12.7%, 37.1%, 45.2% and 40.0% respectively. Candida tropicalis was the most common identifiable organism. Pulmonary IFI caused by invasive aspergillosis was the most common site of infection. The overall case-fatality rate was 50.0% with the highest rate in relapsed leukemia of 92.9%. In multivariable analysis, the age > 4 years, AML, relapsed leukemia and SAA were found to be independent risk factors of IFI with adjusted odds ratio of 2.3, 4.1, 5.1 and 3.7 respectively. In SAA group, only very severe aplastic anemia (ANC < 200 mm3) was found to be associated with development of IFI with odds ratio of 32.7. IFI in Thai children with hematologic diseases appeared to be prevalent with high fatality. Anti-fungal prophylaxis should be considered in patients with SAA to prevent IFI.

1 August 2018 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
PSPanjarat Sowithayasakul
Panjarat Sowithayasakul
PSPhakatip Sinlapamongkolkul
Phakatip Sinlapamongkolkul
JTJitsupa Treetipsatit
Jitsupa Treetipsatit
NVNassawee Vathana
Nassawee Vathana
NNNattee Narkbunnam
Nattee Narkbunnam
JBJassada Buaboonnam
Jassada Buaboonnam
Mediastinal germ cell tumor (MGCT), which accounts for 1% to 3% of extragonadal germ cell tumors, has unique manifestations; it is associated with several types of hematologic malignancy, particularly myeloid neoplasm. The aim of this study was to report the 10-year incidence, clinical characteristics, and outcomes of MGCT at Thailand’s national pediatric tertiary referral center. This retrospective study included patients diagnosed with MGCT at the Department of Pediatrics, Siriraj Hospital during 2005 to 2014. Eight patients (all male) were diagnosed with MGCT. Five of 8 patients were found to have hematologic abnormalities. Three patients were diagnosed with acute myeloid leukemia (AML) (one patient with M1, another having M7, and the other with M0). Another patient had mixed MGCT with mediastinal myeloid sarcoma (MMS). The other patient had malignancy-associated hemophagocytic lymphohistiocytosis syndrome (M-HLH). Isochromosome 12p was detected in 3 patients (AML [2], mixed MGCT/MMS [1]). Four of 5 patients with hematologic abnormalities died of hematologic abnormalities or treatment complication (AML [3], M-HLH [1]). One patient with mixed MGCT/MMS survived with chemotherapy. All patients with AML and MMS were nonseminomatous MGCT and the onset of myeloid malignancies were within 1 year after the diagnosis of MGCT. Associated hematologic malignancies should be suspected in MGCT with abnormal blood count or hematologic symptoms. Isochromosome 12p was the most common cytogenetic finding in MGCT-associated myeloid malignancies patients. Those with nonseminomatous MGCT should have their blood count carefully monitored especially during the first year after the diagnosis of MGCT. Better treatment alternatives for MGCT with associated hematologic malignancies are warranted to ameliorate adverse outcomes.

27 August 2020 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
CTChayamon Takpradit
Chayamon Takpradit
VVVip Viprakasit
Vip Viprakasit
NNNattee Narkbunnam
Nattee Narkbunnam
NVNassawee Vathana
Nassawee Vathana
KPKamon Phuakpet
Kamon Phuakpet
JBJassada Buaboonnam
Jassada Buaboonnam

1 January 2023 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
IHIssanun Hunnuan
Issanun Hunnuan
KSKleebsabai Sanpakit
Kleebsabai Sanpakit
OLOrnsuda Lertbannaphong
Ornsuda Lertbannaphong
JBJassada Buaboonnam
Jassada Buaboonnam
Background: Hemoglobin H disease (HbH), a hemoglobinopathy resulting from abnormal alpha globin genes, is classified into two categories: deletional HbH (DHbH) and non-deletional HbH (NDHbH). The alpha-mutation genotypes exhibit a range of clinical anemias, which differentially impact patient growth. Objectives: This retrospective study assessed the growth of HbH patients at Siriraj Hospital, Mahidol University. Methods: Patients diagnosed with HbH between January 2005 and April 2021 were analyzed using growth standard scores of the Thai Society for Pediatric Endocrinology (2022 version) and BMI-for-age Z scores of the World Health Organization. Growth failure was defined as a patient’s height for age exceeding two standard deviations below the mean. Results: Of the 145 HbH patients, 75 (51.7%) had NDHbH, with --SEA/αCSα being the most common genotype (70 patients; 93.3%). The mean baseline hemoglobin level was significantly lower in NDHbH patients than in DHbH patients (8.16 ± 0.93 g/dL vs. 9.51 ± 0.68 g/dL; P < 0.001). Splenomegaly and growth failure prevalences were higher in NDHbH patients (37.3% vs. 0%, with P < 0.001, and 22.7% vs. 8.6%, with P = 0.020, respectively). Multivariable analysis revealed that splenomegaly > 3 cm was associated with growth failure (OR = 4.28; 95% CI, 1.19–15.39; P = 0.026). Conclusions: NDHbH patients exhibited lower hemoglobin levels and more pronounced splenomegaly than DHbH patients. Growth failure can occur in both HbH types but appears more prevalent in NDHbH. Close monitoring of growth velocity is essential, and early treatment interventions may be required to prevent growth failure.

22 June 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KSKleebsabai Sanpakit
Kleebsabai Sanpakit
NNNattee Narkbunnam
Nattee Narkbunnam
JBJassada Buaboonnam
Jassada Buaboonnam
CTChayamon Takpradit
Chayamon Takpradit
VVVip Viprakasit
Vip Viprakasit
BPBunchoo Pongtanakul
Bunchoo Pongtanakul